{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T11:05:23Z","timestamp":1779015923648,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,7]]},"DOI":"10.7759\/cureus.46623","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T11:14:35Z","timestamp":1696677275000},"source":"Crossref","is-referenced-by-count":17,"title":["Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges"],"prefix":"10.7759","author":[{"given":"Skyler","family":"Brandfon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adi","family":"Eylon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur S","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2017.08.002","article-title":"Obesity in America","volume":"13","author":"Rosenthal RJ","year":"2017","unstructured":"Rosenthal RJ, Morton J, Brethauer S, et al.. Obesity in America. Surg Obes Relat Dis. 2017, 13:1643-50. 10.1016\/j.soard.2017.08.002","journal-title":"Surg Obes Relat Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0889-8529(03)00071-9","article-title":"Obesity and type 2 diabetes","volume":"32","author":"Maggio CA","year":"2003","unstructured":"Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin N Am. 2003, 32:805-22. 10.1016\/s0889-8529(03)00071-9","journal-title":"Endocrinol Metab Clin N Am"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(22)00185-7","article-title":"Obesity-related asthma in children and adolescents","volume":"6","author":"Reyes-Angel J","year":"2022","unstructured":"Reyes-Angel J, Kaviany P, Rastogi D, Forno E. Obesity-related asthma in children and adolescents. Lancet Child Adolesc Health. 2022, 6:713-24. 10.1016\/S2352-4642(22)00185-7","journal-title":"Lancet Child Adolesc Health"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/164_2021_558","article-title":"Obesity and obstructive sleep apnea","volume":"274","author":"Bonsignore MR","year":"2022","unstructured":"Bonsignore MR. Obesity and obstructive sleep apnea. Handb Exp Pharmacol. 2022, 274:181-201. 10.1007\/164_2021_558","journal-title":"Handb Exp Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2019.04.001","article-title":"Osteoporosis and osteoarthritis are two sides of the same coin paid for obesity","volume":"70","author":"Oliveira MC","year":"2020","unstructured":"Oliveira MC, Vullings J, van de Loo FA. Osteoporosis and osteoarthritis are two sides of the same coin paid for obesity. Nutrition. 2020, 70:110486. 10.1016\/j.nut.2019.04.001","journal-title":"Nutrition"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity phenotypes, diabetes, and cardiovascular diseases","volume":"126","author":"Pich\u00e9 ME","year":"2020","unstructured":"Pich\u00e9 ME, Tchernof A, Despr\u00e9s JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020, 126:1477-500. 10.1161\/CIRCRESAHA.120.316101","journal-title":"Circ Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/prd.12326","article-title":"The association of periodontal diseases with metabolic syndrome and obesity","volume":"83","author":"Jepsen S","year":"2020","unstructured":"Jepsen S, Suvan J, Deschner J. The association of periodontal diseases with metabolic syndrome and obesity. Periodontol 2000. 2020, 83:125-53. 10.1111\/prd.12326","journal-title":"Periodontol 2000"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnur.2021.07.010","article-title":"Obesity and psychiatric disorders","volume":"56","author":"Perry C","year":"2021","unstructured":"Perry C, Guillory TS, Dilks SS. Obesity and psychiatric disorders. Nurs Clin North Am. 2021, 56:553-63. 10.1016\/j.cnur.2021.07.010","journal-title":"Nurs Clin North Am"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01052-1","article-title":"Cardiovascular morbidity, diabetes and cancer risk among children and adolescents with severe obesity","volume":"19","author":"Bendor CD","year":"2020","unstructured":"Bendor CD, Bardugo A, Pinhas-Hamiel O, Afek A, Twig G. Cardiovascular morbidity, diabetes and cancer risk among children and adolescents with severe obesity. Cardiovasc Diabetol. 2020, 19:79. 10.1186\/s12933-020-01052-1","journal-title":"Cardiovasc Diabetol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-18576","article-title":"Insulin resistance: definition and consequences","volume":"109 Suppl 2","author":"Lebovitz HE","year":"2001","unstructured":"Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes. 2001, 109 Suppl 2:S135-48. 10.1055\/s-2001-18576","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref11","article-title":"Nonpharmacologic and pharmacologic management of weight gain","volume":"60","author":"Greenberg I","year":"1999","unstructured":"Greenberg I, Chan S, Blackburn GL. Nonpharmacologic and pharmacologic management of weight gain. J Clin Psychiatry. 1999, 60:31-6.","journal-title":"J Clin Psychiatry"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden TA","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, et al.. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021, 325:1403-13. 10.1001\/jama.2021.1831","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13030-020-00177-9","article-title":"Personalized cognitive-behavioural therapy for obesity (CBT-OB): theory, strategies and procedures","volume":"14","author":"Dalle Grave R","year":"2020","unstructured":"Dalle Grave R, Sartirana M, Calugi S. Personalized cognitive-behavioural therapy for obesity (CBT-OB): theory, strategies and procedures. Biopsychosoc Med. 2020, 14:5. 10.1186\/s13030-020-00177-9","journal-title":"Biopsychosoc Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/2515690X211043738","article-title":"Complementary and alternative therapies for weight loss: a narrative review","volume":"26","author":"Lua PL","year":"2021","unstructured":"Lua PL, Roslim NA, Ahmad A, Mansor M, Aung MM, Hamzah F. Complementary and alternative therapies for weight loss: a narrative review. J Evid Based Integr Med. 2021, 26:2515690X211043738. 10.1177\/2515690X211043738","journal-title":"J Evid Based Integr Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-020-00422-w","article-title":"Long-term efficacy and safety of anti-obesity treatment: where do we stand?","volume":"10","author":"Tak YJ","year":"2021","unstructured":"Tak YJ, Lee SY. Long-term efficacy and safety of anti-obesity treatment: where do we stand?. Curr Obes Rep. 2021, 10:14-30. 10.1007\/s13679-020-00422-w","journal-title":"Curr Obes Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0803446","article-title":"Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients","volume":"31","author":"Kopelman P","year":"2007","unstructured":"Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, Valensi P. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007, 31:494-9. 10.1038\/sj.ijo.0803446","journal-title":"Int J Obes (Lond)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2009.155","article-title":"Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical)","volume":"18","author":"Kopelman P","year":"2010","unstructured":"Kopelman P, Groot Gde H, Rissanen A, et al.. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010, 18:108-15. 10.1038\/oby.2009.155","journal-title":"Obesity (Silver Spring)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2013.49.12.2099318","article-title":"Cetilistat for the treatment of obesity","volume":"49","author":"Gras J","year":"2013","unstructured":"Gras J. Cetilistat for the treatment of obesity. Drugs Today (Barc). 2013, 49:755-9. 10.1358\/dot.2013.49.12.2099318","journal-title":"Drugs Today (Barc)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6507.20.03369-6","article-title":"Obesity and GLP-1","volume":"46","author":"Perez-Montes DE Oca A","year":"2021","unstructured":"Perez-Montes DE Oca A, Pellitero S, Puig-Domingo M. Obesity and GLP-1. Minerva Endocrinol (Torino). 2021, 46:168-76. 10.23736\/S2724-6507.20.03369-6","journal-title":"Minerva Endocrinol (Torino)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst JJ","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007, 87:1409-39. 10.1152\/physrev.00034.2006","journal-title":"Physiol Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2012.11.008","article-title":"Glucagon-like peptide 1 and appetite","volume":"24","author":"Dailey MJ","year":"2013","unstructured":"Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab. 2013, 24:85-91. 10.1016\/j.tem.2012.11.008","journal-title":"Trends Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315620180","article-title":"The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity","volume":"7","author":"Crane J","year":"2016","unstructured":"Crane J, McGowan B. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis. 2016, 7:92-107. 10.1177\/2040622315620180","journal-title":"Ther Adv Chronic Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"Ding X","year":"2006","unstructured":"Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice. Hepatology. 2006, 43:173-81. 10.1002\/hep.21006","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.5.1026","article-title":"Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob\/ob, db\/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)","volume":"48","author":"Young AA","year":"1999","unstructured":"Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob\/ob, db\/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes. 1999, 48:1026-34. 10.2337\/diabetes.48.5.1026","journal-title":"Diabetes"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo RA","year":"2005","unstructured":"DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005, 28:1092-100. 10.2337\/diacare.28.5.1092","journal-title":"Diabetes Care"},{"key":"ref26","article-title":"Exenatide","author":"Bridges A","year":"2023","unstructured":"Bridges A, Bistas KG, Jacobs TF. Exenatide. StatPearls Publishing, Treasure Island, Florida; 2023. https:\/\/pubmed.ncbi.nlm.nih.gov\/30085523\/."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.111625","article-title":"Glucagon-like peptide-1 analogues: an overview","volume":"17","author":"Gupta V","year":"2013","unstructured":"Gupta V. Glucagon-like peptide-1 analogues: an overview. Indian J Endocrinol Metab. 2013, 17:413-21. 10.4103\/2230-8210.111625","journal-title":"Indian J Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.17925\/EE.2022.18.1.43","article-title":"Glucagon-like peptide-1 receptor analogues for the treatment of obesity","volume":"18","author":"Williams DM","year":"2022","unstructured":"Williams DM, Staff M, Bain SC, Min T. Glucagon-like peptide-1 receptor analogues for the treatment of obesity. touchREV Endocrinol. 2022, 18:43-8. 10.17925\/EE.2022.18.1.43","journal-title":"touchREV Endocrinol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen LB","year":"2019","unstructured":"Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019, 10:155. 10.3389\/fendo.2019.00155","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0871-0","article-title":"Semaglutide: first global approval","volume":"78","author":"Dhillon S","year":"2018","unstructured":"Dhillon S. Semaglutide: first global approval. Drugs. 2018, 78:275-84. 10.1007\/s40265-018-0871-0","journal-title":"Drugs"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"fficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil PM","year":"2018","unstructured":"O'Neil PM, Birkenfeld AL, McGowan B, et al.. fficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018, 392:637-49. 10.1016\/S0140-6736(18)31773-2","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies M","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, et al.. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021, 397:971-984. 10.1016\/S0140-6736(21)00213-0","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the step 8 randomized clinical trial","volume":"327","author":"Rubino DM","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, et al.. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the step 8 randomized clinical trial. JAMA. 2022, 327:138-50. 10.1001\/jama.2021.23619","journal-title":"JAMA"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31982","article-title":"Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity","volume":"5","author":"Ghusn W","year":"2022","unstructured":"Ghusn W, De la Rosa A, Sacoto D, et al.. Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open. 2022, 5:e2231982. 10.1001\/jamanetworkopen.2022.31982","journal-title":"JAMA Netw Open"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/372425a0","article-title":"Positional cloning of the mouse obese gene and its human homologue","volume":"372","author":"Zhang Y","year":"1994","unstructured":"Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994, 372:425-32. 10.1038\/372425a0","journal-title":"Nature"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-2-201001190-00008","article-title":"Narrative review: the role of leptin in human physiology: emerging clinical applications","volume":"152","author":"Kelesidis T","year":"2010","unstructured":"Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med. 2010, 152:93-100. 10.7326\/0003-4819-152-2-201001190-00008","journal-title":"Ann Intern Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113196660743","article-title":"Leptin and the OB-receptor as anti-obesity target: recent in silico advances in the comprehension of the protein-protein interaction and rational drug design of anti- obesity lead compounds","volume":"20","author":"Tutone M","year":"2014","unstructured":"Tutone M, Lauria A, Almerico AM. Leptin and the OB-receptor as anti-obesity target: recent in silico advances in the comprehension of the protein-protein interaction and rational drug design of anti- obesity lead compounds. Curr Pharm Des. 2014, 20:136-45. 10.2174\/13816128113196660743","journal-title":"Curr Pharm Des"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-013-0263-5","article-title":"Leptin signaling and leptin resistance","volume":"7","author":"Zhou Y","year":"2013","unstructured":"Zhou Y, Rui L. Leptin signaling and leptin resistance. Front Med. 2013, 7:207-22. 10.1007\/s11684-013-0263-5","journal-title":"Front Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1052789","article-title":"Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives","volume":"15","author":"Tchang BG","year":"2015","unstructured":"Tchang BG, Shukla AP, Aronne LJ. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives. Expert Opin Biol Ther. 2015, 15:1061-75. 10.1517\/14712598.2015.1052789","journal-title":"Expert Opin Biol Ther"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2016.1096772","article-title":"Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy","volume":"9","author":"Meehan CA","year":"2016","unstructured":"Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. Expert Rev Clin Pharmacol. 2016, 9:59-68. 10.1586\/17512433.2016.1096772","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1210\/er.2009-0037","article-title":"The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology","volume":"31","author":"Tao YX","year":"2010","unstructured":"Tao YX. The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology. Endocr Rev. 2010, 31:506-43. 10.1210\/er.2009-0037","journal-title":"Endocr Rev"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00515","article-title":"Signal transduction and pathogenic modifications at the melanocortin-4 receptor: a structural perspective","volume":"10","author":"Heyder N","year":"2019","unstructured":"Heyder N, Kleinau G, Szczepek M, et al.. Signal transduction and pathogenic modifications at the melanocortin-4 receptor: a structural perspective. Front Endocrinol (Lausanne). 2019, 10:515. 10.3389\/fendo.2019.00515","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4202","article-title":"Melanocortin-4 receptor-regulated energy homeostasis","volume":"19","author":"Krashes MJ","year":"2016","unstructured":"Krashes MJ, Lowell BB, Garfield AS. Melanocortin-4 receptor-regulated energy homeostasis. Nat Neurosci. 2016, 19:206-19. 10.1038\/nn.4202","journal-title":"Nat Neurosci"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.80","article-title":"The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options","volume":"38","author":"Fani L","year":"2014","unstructured":"Fani L, Bak S, Delhanty P, van Rossum EF, van den Akker EL. The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options. Int J Obes (Lond). 2014, 38:163-9. 10.1038\/ijo.2013.80","journal-title":"Int J Obes (Lond)"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2017.06.015","article-title":"Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency","volume":"6","author":"Collet TH","year":"2017","unstructured":"Collet TH, Dubern B, Mokrosinski J, et al.. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab. 2017, 6:1321-9. 10.1016\/j.molmet.2017.06.015","journal-title":"Mol Metab"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.689387","article-title":"Two cases with an early presented proopiomelanocortin deficiency-a long-term follow-up and systematic literature review","volume":"12","author":"Gregoric N","year":"2021","unstructured":"Gregoric N, Groselj U, Bratina N, et al.. Two cases with an early presented proopiomelanocortin deficiency-a long-term follow-up and systematic literature review. Front Endocrinol (Lausanne). 2021, 12:689387. 10.3389\/fendo.2021.689387","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2207442","article-title":"Long-term MC4R agonist treatment in POMC-deficient patients","volume":"387","author":"K\u00fchnen P","year":"2022","unstructured":"K\u00fchnen P, Cl\u00e9ment K. Long-term MC4R agonist treatment in POMC-deficient patients. N Engl J Med. 2022, 387:852-4. 10.1056\/NEJMc2207442","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30364-8","article-title":"Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials","volume":"8","author":"Cl\u00e9ment K","year":"2020","unstructured":"Cl\u00e9ment K, van den Akker E, Argente J, et al.. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020, 8:960-70. 10.1016\/S2213-8587(20)30364-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1177\/87551225221116010","article-title":"Setmelanotide: a novel targeted treatment for monogenic obesity","volume":"38","author":"Pressley H","year":"2022","unstructured":"Pressley H, Cornelio CK, Adams EN. Setmelanotide: a novel targeted treatment for monogenic obesity. J Pharm Technol. 2022, 38:368-73. 10.1177\/87551225221116010","journal-title":"J Pharm Technol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-019-0951-x","article-title":"Melanocortin-4 receptors and sympathetic nervous system activation in hypertension","volume":"21","author":"da Silva AA","year":"2019","unstructured":"da Silva AA, do Carmo JM, Wang Z, Hall JE. Melanocortin-4 receptors and sympathetic nervous system activation in hypertension. Curr Hypertens Rep. 2019, 21:46. 10.1007\/s11906-019-0951-x","journal-title":"Curr Hypertens Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/187632-advances-in-anti-obesity-pharmacotherapy-current-treatments-emerging-therapies-and-challenges","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:08:54Z","timestamp":1707509334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/187632-advances-in-anti-obesity-pharmacotherapy-current-treatments-emerging-therapies-and-challenges"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,7]]},"references-count":51,"URL":"https:\/\/doi.org\/10.7759\/cureus.46623","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,7]]}}}